Minghui Wang
Jinan, 250000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Long non-coding RNA NAV2-AS2 protects against atherosclerosis by regulating EndMT through sense-antisense hybrid formation with NAV2 mRNA.
Journal: International journal of biological macromolecules
Published: March 17, 2025
A novel EndMT inhibitor, xanthotoxin, attenuates non-alcoholic fatty liver disease by acting as TGFβR2 antagonist.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: February 07, 2025
PD-1 inhibition disrupts collagen homeostasis and aggravates cardiac dysfunction through endothelial-fibroblast crosstalk and EndMT.
Journal: Frontiers in pharmacology
Published: December 21, 2024
LncRNA NAV2-AS2 is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis.
Journal: International journal of biological macromolecules
Published: October 22, 2024
Non-coding RNAs: targets for Chinese herbal medicine in treating myocardial fibrosis.
Journal: Frontiers in pharmacology
Published: November 13, 2023
Communication between nonalcoholic fatty liver disease and atherosclerosis: Focusing on exosomes.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: October 11, 2023
Anti-atherosclerosis mechanisms associated with regulation of non-coding RNAs by active monomers of traditional Chinese medicine.
Journal: Frontiers in pharmacology
Published: August 26, 2023
(Ni,Co)Se@Ni(OH)2 heterojunction nanosheets as an efficient electrocatalyst for the hydrogen evolution reaction.
Journal: Dalton transactions (Cambridge, England : 2003)
Published: December 15, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026